MTD vs SYRE
Mettler Toledo vs Spyre Therapeutics, Inc. — AI-powered side-by-side comparison
MTD
Mettler Toledo
64
Buy
VS
SYRE
Spyre Therapeutics, Inc.
67
Buy
| Metric | MTD | SYRE |
|---|
| AI Score |
64
|
67
|
| Price |
$1,402.84
|
$93.00
|
| P/E Ratio |
31.43×
|
-54.69×
|
| ROE |
-3677.4%
|
-21.7%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
59.3%
|
0.0%
|
| Debt / Equity |
164.70×
|
0.00×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
45.7
|
57.5
|
| Beta |
1.224
|
3.026
|
| Expected Upside |
+7.9%
|
—
|
AI Committee View
Current Innellis committee reasoning for MTD versus SYRE.
SYRE leads by 3 points.
SYRE scores 67/100 (Buy) versus MTD at 64/100 (Buy).
MTD Committee View
50% agreement
4 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- MACD histogram negative -- bearish momentum — Technical
- Daily trend (uptrend) conflicts with the weekly trend (downtrend) -- fighting the larger trend — Technical
SYRE Committee View
67% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
Bear Case
- ROE of only -24.3% -- cheap may mean cheap for a reason — Value
- MACD histogram negative -- bearish momentum — Technical
- Weekly RSI at 81 -- overbought on the larger timeframe too — Technical